An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The
Researchers at Queen Mary, University of London, studied equivalent cells taken from mouse brains. Principal investigator Silvia Marino, Professor of Neuropathology at Queen Mary, University of London, and her team showed that medulloblastomas can grow from a type of brain stem cell and that these cancers are a distinct form of the disease which may require a completely different approach to treatment.
Like a Hole in the Head: Living with a Brain Tumour
Image by hoodiefanatic via Flickr
The key to eradicating tumors and preventing relapses and metastasis is buried within the tumor itself. The tumor cells themselves contain a sort of needle in the haystack. Just 1% of the total volume of the tumor is responsible for reproduction, and a targeted surgery or drugs could be sufficient enough to “deactivate” the tumor and avoid any possibility of a reoccurrence. This type of treatment could possibly change the therapeutic approach to malignant tumors according to an Italian study at the Superior Health Institute (ISS) by Professor Ruggero De Maria, the Director
What are the biological processes that stem cells go through? What are the industrial processes we need to manufacturing? What do we know about cancer stem cells? How do iPS cells fit into the picture vs. embryonic stem cells? In this episode we investigate how the science and research of stem cells is being translated into industrial cell processes to create FDA approvable, and commercializable products. Differentiation, proliferation, migration, retro-differentiation, trans-differentiation, transformation into cancer cells, the role of tumors‘ micro environments and epigenetics and all reviewed here by the field’s foremost experts.
Research has indicated that certain sarcomas come from the mesenchymal stem cells. However, expression of neural stem cells has been noted in others. Identifying and isolating mesenchymal stem cells and neural stem cells relies on finding specific proteins expressed by both types.
In this study, eight different markers representing proteins associated with these two types of stem cells were applied to the 81 tumors. Through cluster analysis, the researchers organized the data into groups showing similar patterns. Two major subgroups of pediatric sarcomas emerged